GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ondine Biomedical Inc (OTCPK:OBIMF) » Definitions » Return-on-Tangible-Asset

OBIMF (Ondine Biomedical) Return-on-Tangible-Asset : -314.19% (As of Jun. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Ondine Biomedical Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Ondine Biomedical's annualized Net Income for the quarter that ended in Jun. 2024 was $-11.33 Mil. Ondine Biomedical's average total tangible assets for the quarter that ended in Jun. 2024 was $3.61 Mil. Therefore, Ondine Biomedical's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2024 was -314.19%.

The historical rank and industry rank for Ondine Biomedical's Return-on-Tangible-Asset or its related term are showing as below:

OBIMF' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -746.52   Med: -222.35   Max: -77.86
Current: -246.17

During the past 13 years, Ondine Biomedical's highest Return-on-Tangible-Asset was -77.86%. The lowest was -746.52%. And the median was -222.35%.

OBIMF's Return-on-Tangible-Asset is ranked worse than
92.67% of 1501 companies
in the Biotechnology industry
Industry Median: -38.29 vs OBIMF: -246.17

Ondine Biomedical Return-on-Tangible-Asset Historical Data

The historical data trend for Ondine Biomedical's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ondine Biomedical Return-on-Tangible-Asset Chart

Ondine Biomedical Annual Data
Trend Dec08 Dec09 Dec10 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only -635.74 -754.78 -273.67 -73.37 -130.44

Ondine Biomedical Semi-Annual Data
Dec07 Jun08 Dec08 Jun09 Dec09 Jun10 Dec10 Jun11 Dec17 Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -57.65 -99.50 -133.84 -197.16 -314.19

Competitive Comparison of Ondine Biomedical's Return-on-Tangible-Asset

For the Biotechnology subindustry, Ondine Biomedical's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ondine Biomedical's Return-on-Tangible-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ondine Biomedical's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Ondine Biomedical's Return-on-Tangible-Asset falls into.


;
;

Ondine Biomedical Return-on-Tangible-Asset Calculation

Ondine Biomedical's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-10.742/( (12.197+4.274)/ 2 )
=-10.742/8.2355
=-130.44 %

Ondine Biomedical's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Jun. 2024 )  (Q: Dec. 2023 )(Q: Jun. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Jun. 2024 )  (Q: Dec. 2023 )(Q: Jun. 2024 )
=-11.328/( (4.274+2.937)/ 2 )
=-11.328/3.6055
=-314.19 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is two times the semi-annual (Jun. 2024) net income data.


Ondine Biomedical  (OTCPK:OBIMF) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Ondine Biomedical Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Ondine Biomedical's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Ondine Biomedical Business Description

Traded in Other Exchanges
Address
1100 Melville Street, Suite 888, Vancouver, BC, CAN, V6E4A6
Ondine Biomedical Inc is a life sciences company, focusing on the development of photodisinfection-based therapies to provide solutions to drug-resistant infections. The company has created a platform technology called antimicrobial photodynamic disinfection, or photodisinfection, to help prevent and help treat infections across different therapeutic areas in healthcare and industry settings. Canada is the major revenue generator for the group. The company has one reportable operating segment that is antimicrobial photodynamic therapy (aPDT) products.